87 related articles for article (PubMed ID: 11673526)
1. Efficient chromosomal mapping of a methylcholanthrene-induced tumor antigen by CTL immunoselection.
Akilesh S; Dudley ME; Eden PA; Roopenian DC
J Immunol; 2001 Nov; 167(9):5143-9. PubMed ID: 11673526
[TBL] [Abstract][Full Text] [Related]
2. Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens.
Dudley ME; Roopenian DC
J Exp Med; 1996 Aug; 184(2):441-7. PubMed ID: 8760797
[TBL] [Abstract][Full Text] [Related]
3. Characterization of cloned class I MHC-restricted, CD8+ anti-Meth A cytotoxic T-lymphocytes: recognition of an epitope derived from the Meth A gp110 tumor rejection antigen.
Fassanito MA; Loftus D; De Leo RM; Law LW; Appella E; De Leo AB
Cancer Res; 1994 Aug; 54(16):4424-9. PubMed ID: 7519121
[TBL] [Abstract][Full Text] [Related]
4. Chromosome assignment of the tumor-specific antigen of a 3-methylcholanthrene-induced mouse sarcoma.
Pravtcheva DD; DeLeo AB; Ruddle FH; Old LJ
J Exp Med; 1981 Sep; 154(3):964-77. PubMed ID: 7276830
[TBL] [Abstract][Full Text] [Related]
5. Gene mapping in a murine cell line by immunoselection with cytotoxic T lymphocytes.
Zuberi AR; Dudley ME; Christianson GJ; Roopenian DC
Genomics; 1994 Jan; 19(2):273-9. PubMed ID: 7514566
[TBL] [Abstract][Full Text] [Related]
6. DNA vaccination primes MHC class I-restricted, simian virus 40 large tumor antigen-specific CTL in H-2d mice that reject syngeneic tumors.
Schirmbeck R; Böhm W; Reimann J
J Immunol; 1996 Oct; 157(8):3550-8. PubMed ID: 8871655
[TBL] [Abstract][Full Text] [Related]
7. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen.
Rice J; Buchan S; Stevenson FK
J Immunol; 2002 Oct; 169(7):3908-13. PubMed ID: 12244189
[TBL] [Abstract][Full Text] [Related]
8. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones.
Maryanski JL; Boon T
Eur J Immunol; 1982 May; 12(5):406-12. PubMed ID: 6178608
[TBL] [Abstract][Full Text] [Related]
9. Deletion mapping by immunoselection against the H-Y histocompatibility antigen further resolves the Sxra region of the mouse Y chromosome and reveals complexity of the Hya locus.
King TR; Christianson GJ; Mitchell MJ; Bishop CE; Scott D; Ehrmann I; Simpson E; Eicher EM; Roopenian DC
Genomics; 1994 Nov; 24(1):159-68. PubMed ID: 7896271
[TBL] [Abstract][Full Text] [Related]
10. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
[TBL] [Abstract][Full Text] [Related]
11. In vitro selection of SV40 T antigen epitope loss variants by site-specific cytotoxic T lymphocyte clones.
Tanaka Y; Tevethia SS
J Immunol; 1988 Jun; 140(12):4348-54. PubMed ID: 2453578
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic T lymphocytes (CTL) against a transforming gene product select for transformed cells with point mutations within sequences encoding CTL recognition epitopes.
Lill NL; Tevethia MJ; Hendrickson WG; Tevethia SS
J Exp Med; 1992 Aug; 176(2):449-57. PubMed ID: 1380062
[TBL] [Abstract][Full Text] [Related]
13. Identification of Meth A sarcoma-derived class I major histocompatibility complex-associated peptides recognized by a specific CD8+ cytotoxic T lymphocyte.
Frassanito MA; Mayordomo JI; DeLeo RM; Storkus WJ; Lotze MT; DeLeo AB
Cancer Res; 1995 Jan; 55(1):124-8. PubMed ID: 7528638
[TBL] [Abstract][Full Text] [Related]
14. Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL.
Nelson DJ; Mukherjee S; Bundell C; Fisher S; van Hagen D; Robinson B
J Immunol; 2001 May; 166(9):5557-66. PubMed ID: 11313395
[TBL] [Abstract][Full Text] [Related]
15. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha.
Tüting T; Wilson CC; Martin DM; Kasamon YL; Rowles J; Ma DI; Slingluff CL; Wagner SN; van der Bruggen P; Baar J; Lotze MT; Storkus WJ
J Immunol; 1998 Feb; 160(3):1139-47. PubMed ID: 9570527
[TBL] [Abstract][Full Text] [Related]
16. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele.
Crowley NJ; Darrow TL; Quinn-Allen MA; Seigler HF
J Immunol; 1991 Mar; 146(5):1692-9. PubMed ID: 1671580
[TBL] [Abstract][Full Text] [Related]
17. Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice.
Kavunja HW; Lang S; Sungsuwan S; Yin Z; Huang X
Cancer Immunol Immunother; 2017 Apr; 66(4):451-460. PubMed ID: 28011995
[TBL] [Abstract][Full Text] [Related]
18. Loss of heterozygosity and mitotic linkage maps in the mouse.
Henson V; Palmer L; Banks S; Nadeau JH; Carlson GA
Proc Natl Acad Sci U S A; 1991 Aug; 88(15):6486-90. PubMed ID: 1677769
[TBL] [Abstract][Full Text] [Related]
19. Recruitment of CTL activity by tumor-specific antibody-mediated targeting of single-chain class I MHC-peptide complexes.
Lev A; Novak H; Segal D; Reiter Y
J Immunol; 2002 Sep; 169(6):2988-96. PubMed ID: 12218113
[TBL] [Abstract][Full Text] [Related]
20. Effect of point mutations in the native simian virus 40 tumor antigen, and in synthetic peptides corresponding to the H-2Db-restricted epitopes, on antigen presentation and recognition by cytotoxic T lymphocyte clones.
Deckhut AM; Tevethia SS
J Immunol; 1992 May; 148(10):3012-20. PubMed ID: 1374447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
